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Abstract 
 
Many studies have demonstrated that increased levels of free fatty acids (FFAs) are 
associated with increased apoptosis in hepatocytes, podocytes, myocytes, and pancreatic islet 
cells.  However, the effects of FAAs on neuronal cell function are not well characterized.  In this 
study, mouse neuroblastoma cells from the Neuro-2a (N2a) cell line were treated with either 
bovine serum albumin (BSA) or different concentrations of BSA-conjugated palmitate (PA) and 
examined cell viability using MTT assay.  Concentrations of PA at or above 200 μM in the 
growth media were associated with a decrease in cell viability.  In order to examine whether N-
acetylcysteine (NAC) or sodium phenylbutyrate (PB) affected the PA-induced decrease in cell 
viability, N2a cells were treated with PA in combination with either NAC or PB and cell 
viability was measured using MTT assay.  Neither NAC in concentrations of up to 200 μM nor 
PB in concentrations of up to 1 mM was able to attenuate the PA-induced decrease in N2a 
viability.  When viewed under a microscope PA treated cells exhibited increased irregularity in 
size and shape as compared to cells treated with BSA.  In order to examine whether PA treatment 
affected insulin signaling in this cell line, N2a cells were treated with 200 μM PA for 24 hours 
followed by stimulation with 25 ng/mL insulin for 0, 5, or 10 minutes.  Activation of AKT1 and 
GSK-3β was then analyzed by Western blot assay.  Preliminary results suggested that while 
insulin-induced GSK-3β activation may not be affected by PA treatment, insulin-induced AKT1 
activation appeared to be attenuated by PA treatment as compared to BSA-treated controls.  
These results remain to be confirmed and the mechanism of the PA-induced changes in viability 
and insulin signaling remain to be defined. 
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Introduction 
 
Obesity, defined as a body mass index (BMI) of 30 or greater, is a growing public health 
concern in the United States.  According to the 2010 data from the CDC approximately 36% of 
adults and 17% of children in the U.S. were categorized as obese.
1
   Obesity is associated with a 
number of comorbid medical conditions including hypertension, coronary artery disease, stroke, 
sleep apnea, non-alcoholic fatty liver disease, the development of several types of cancer, and 
type 2 diabetes.
2-5
   
Individuals with type 2 diabetes experience a systemic insensitivity to the effects of 
insulin, a decreased compensatory insulin secretion response, and a consequent increase in blood 
glucose levels.
6  
Insulin is a peptide hormone that is central to proper glucose metabolism.  When 
blood glucose levels become elevated insulin is released from the β islet cells of the pancreas.  
On binding to its receptor, this hormone initiates a complex intracellular signal transduction 
cascade.
7
 One of the most important metabolic effects of this cascade is the translocation of the 
Glut4 transporter from intracellular stores to the plasma membrane in adipocytes and myocytes, 
which promotes glucose uptake by these cells.  Insulin also promotes glycogen synthesis and 
inhibits lipolysis, both of which are important for maintaining the proper energy balance in an 
organism.
8
 In addition to its metabolic effects, this hormone also promotes protein synthesis as 
well as cell survival, differentiation, and proliferation.
9-10 
While insulin may alter the subcellular localization of neuronal glucose transporters, 
unlike some other tissues neurons do not appear to experience increased glucose uptake solely in 
response to insulin exposure.
11
  Despite this fact, neurons express the insulin cell-surface 
receptor and  studies suggest that insulin signaling plays an important role in proper neuronal 
function.
12
 Insulin signaling is impaired in the neurons of several mouse strains that are used as 
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models for type 2 diabetes and are prone to developing diabetic neuropathy, a condition 
characterized by peripheral nerve dysfunction.
13-14
  Attenuated insulin signaling has also been 
associated with decreased cognitive performance and the formation of β-amyloid plaques 
commonly found in Alzheimer’s disease.15-16 
Protein kinase B, also known as AKT, serves a crucial role in mediating many of the 
effects of the insulin signaling pathway.  This serine/threonine kinase is activated by 
phosphorylation as part of the cascade which, in turn, phosphorylates a number of downstream 
effector molecules. Among these targets are glycogen synthase kinase 3β (GSK-3β), which is 
involved in regulating glycogen synthesis, and Bcl-2-associated death protein, which is involved 
in initiating apoptosis.
17
  
One of the most common clinical findings in obese individuals is an elevated level of free 
fatty acids (FFAs) in the blood.
18
 In vitro studies have been performed in a number of different 
tissues, including hepatocytes, podocytes, myocytes, and pancreatic islet cells to examine the 
effects of exposure to these elevated FFA levels.  One of the common cellular effects of FFA 
exposure for periods greater than 12 hours is the induction of apoptosis in these cell types.
19-22
 
Prolonged treatment with elevated FFA levels has also been associated in vitro with impaired 
AKT1 activation and a consequent decrease in insulin signaling in hepatocytes and adipocytes.
23-
24
   
While the exact mechanism underlying these changes remains unclear, endoplasmic 
reticulum (ER) and oxidative stress caused by FFA exposure have both been proposed as 
causative factors in impaired insulin signaling.  According to the ER stress theory prolonged 
exposure to FFAs causes unfolded proteins to accumulate in the ER.  This buildup triggers the 
initiation of the cellular unfolded protein response.  As a part of this response c-Jun amino-
4 
 
terminal kinase (JNK) is activated and subsequently adds inhibitory serine phosphorylations to 
components of the insulin signaling cascade.
25
  The oxidative stress theory states that the 
increased intracellular FFA load leads to an increase in β-oxidation and a consequent rise in 
reactive oxygen species (ROS) production.  These ROS, in turn, activate kinases such as JNK 
and p38 which phosphorylate and attenuate the action of components of the insulin signaling 
pathway.
26 
 Both ER stress and ROS generation have also been implicated in the induction of 
apoptosis.
27-28 
Though there have been significant studies to examine the effects FFA exposure on cell 
survival and insulin signaling in liver, muscle, pancreatic islet cells, and other peripheral tissues, 
the impact of such treatments on neuronal tissue has not been well characterized.  We first 
examined the effects of PA exposure on the viability of the N2a cells by MTT assay.  We then 
treated cells with PA in combination with either NAC, an ROS scavenger, or PB, a chemical that 
has been shown to reduce ER stress, in an effort to determine whether oxidative or ER stresses 
contribute to PA-induced changes in N2a viability.  We also used a microscope to visualize cells 
after PA treatment to study any morphological changes.  Finally, we sought to examine the 
effects PA treatment on insulin signaling in N2a cells through Western blotting. 
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Materials and Methods 
 
Cell Culture 
 Neuro-2a (N2a), a murine neuroblastoma cell line, was purchased from the American 
Type Culture Collection (ATCC, Manassas, VA).  These cells were maintained in Eagle's 
Modified Essential Medium (EMEM) containing 10% fetal bovine serum (FBS) and 1% 
pen/strep antibiotic.  Cells were cultured at 37°C in a humidified incubator with 5% CO2.   
 
MTT Assay 
 N2a cells were seeded into a 96-well cell culture plate at 2.5x10
3
 cells per well in EMEM 
containing FBS and pen/strep as described above.  One day after seeding, cells were treated as 
follows.  For the PA dose response experiment, cells were treated with 0, 25, 50, 100, 200, 400, 
or 600 μM PA for 24 hours.  For the PA/NAC cotreatment experiment, cells were treated with 
either 2.4 mg/mL BSA or 200 μM PA in combination with 0, 25, 50, 100, or 200 μM NAC for 
24 hours.  For the PA/PB cotreatment experiment, cells were treated with either 2.4 mg/mL BSA 
or 200 μM PA in combination with 0, 25, 50, 100, 200, 500, or 1000 μM PB for 24 hours.  Each 
well then received 10 μL of 5 mg/mL MTT and incubated for 4 hours.  At the end of this 
incubation, 100 μL of solubilization reagent was added to each well of the cell culture plate.  The 
plate was rested at room temperature for 10 minutes to allow complete dissolution of all 
formazan crystals and read at 560 nm using a Spectramax M5 plate reader (Molecular Dynamics, 
Sunnyvale, CA).  Absorbance values for each treatment group were normalized to the control 
group to determine relative cell viability. 
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Microscopy 
N2a cells were seeded into 6-well culture plate at 2.0x10
5
, incubated overnight, and 
rinsed with PBS.  The media was then replaced with serum-free EMEM and treated with 2.4 
mg/mL BSA or PA at 100, 200, or 400 μM and incubated for 24 hours.  At the end of the 
treatment period, the cells were washed with PBS to remove non-adherent cells before being 
imaged at 400X magnification using an Amscope MU1000 camera and the ToupView software 
(ToupTek Photonics). 
 
Insulin Time Course 
 N2a cells were seeded into 6-well culture plates at 1.8x10
5
 cells per well.  One day after 
seeding the cells were rinsed with PBS.  The media was then replaced with serum-free EMEM 
supplemented with 2.4 mg/mL BSA and incubated for 24 hours before being treated with 25 
ng/mL insulin for 0, 5, or 10 minutes.   
 
Palmitate Treatment 
 N2a cells were seeded into 6-well culture plates at 1.8x10
5
 cells per well for control wells 
and 3.0x10
5
 cells per well for PA treatment wells.  One day after seeding, the cells were rinsed 
with PBS.  The media was then replaced with serum-free EMEM and treated with 2.4 mg/mL 
BSA for control wells and 200 μM PA for PA treatment wells.  Cells were incubated for 24 
hours before being treated with 25 ng/mL insulin for 0, 5, or 10 minutes. 
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Protein Extraction 
 At the end of the treatment period, media was aspirated from the wells of 6-well cell 
culture plates.  The cells were washed with Hank's balanced salt solution, then 100 μL of 1X cell 
lysis buffer (0.0625M Tris, 0.05 M dithiothreitol, 10% glycerol, 2% sodium dodecyl sulfate, 
0.01% bromophenol blue) was added to each well.  Samples were then collected and sonicated 
using a 550 Sonic Dismembrator (Fischer Scientific, Pittsburgh, PA) for 15 pulses while on ice. 
 
Western Blot Analysis 
 Aliquots of lysed protein samples were taken from the protein extraction samples, heated 
to 95°C for 5 minutes, and then centrifuged at 10000 rpm for 5 minutes.  Aliquots were then 
loaded into 10% (w/v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
gels and resolved by electrophoresis performed at 100V.  Protein was then transferred from the 
gels to nitrocellulose membranes electrophoretically.  The membranes were blocked with 
Superblock (ThermoScientific, Logan, UT) for 1 hour at room temperature, then incubated with 
primary antibodies immunoreactive against phospho-AKT1 (Epitomics, Burlingame, CA) or 
phospho-GSK-3β (Santa Cruz Biotechnology, Dallas, TX) at appropriate dilutions overnight at 
4°C.  Membranes were washed with tris-buffered saline with 0.1% Tween-20 (TBST), then 
incubated in horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 hour at room 
temperature.  Membranes were washed again in TBST and developed using the ECL Plus 
detection kit (ThermoScientific, Logan, UT).  Images of the membranes were generated using a 
Storm 860 Molecular Imager (Molecular Dynamics) and quantified using the Image J program 
from the National Institutes of Health.  Following this, the membranes were stripped and 
reprobed with primary antibodies immunoreactive against total AKT1 or total GSK-3β.  Band 
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intensities for p-AKT1and p-GSK-3β were then normalized to total AKT-1 or GSK-3β 
respectively and plotted.   
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Results 
 
Effects of PA Treatment on N2a Cell Viability 
 To determine the effects of PA exposure on neuronal cell viability, cells were seeded into 
a 96-well culture plate and allowed to rest overnight.  They were then treated with PA at 0, 25, 
50, 100, 200, 400 or 600 μM for 24 hours before cell viability was analyzed by MTT assay.   
 Analysis of the data revealed an 8% increase in N2a cell viability following treatment 
with 25 μM PA, while the 50 μM and 100 μM treatment groups showed no significant difference 
in cell viability when compared to control.  As the concentration of PA treatment continued to 
increase, cell viability decreased in a dose-dependent manner.  The 200 μM, 400 μM,  
and 600 μM treatment groups experienced a 20%, 28%, and 34% reduction in cell viability 
respectively (Fig. 1).  
 
Effects of PA/NAC Cotreatment on N2a Cell Viability 
 To study the effects of NAC on PA-induced changes in cell viability we seeded N2a cells 
into a 96-well culture plate and, following an overnight rest, treated them with either 2.4 mg/mL 
BSA or 200 μM PA for 24 hours.  Cells in each group were cotreated with 0, 25, 50, 100, or 200 
Fig 1 Effects of PA 
Treatment on Cell Viability 
as Measured by MTT Assay 
N2a cells were seeded and 
treated with PA at the 
indicated concentrations for 
24 hours.  Cell viability was 
then measured via MTT 
assay.  Data are presented as 
mean ±  SD; n=12.  * 
indicates significant 
difference from the 0 μM PA 
treatment group, p<0.05. 
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μM NAC for the same duration.  At the end of this incubation period an MTT assay was used to 
determine cell viability in each treatment group.  Data were normalized to the untreated control 
group. 
 None of the concentrations of NAC used for treatment induced a significant change in 
cell viability in the BSA treatment groups when compared to the untreated control.    Cells 
treated with PA and 0 μM NAC exhibited a 22% decrease in cell viability compared to BSA 
treated cells.  Increased concentrations of NAC up to 200 μM did not have any significant effects 
on the reduction in cell viability induced by PA (Fig. 2). 
 
 
Effects of PA/PB Cotreatment on N2a Cell Viability 
 To investigate the effects of PB on PA-induced changes in cell viability N2a cells were 
seeded into a 96-well culture plate and allowed them to rest overnight.  We then treated them 
with either 2.4 mg/mL BSA or 200 μM PA and cotreated with 0, 25, 50, 100, 200, 500 μM, or 1 
Fig 2 Effects of PA/NAC 
Cotreatment on N2a Cell Viability 
as Measured by MTT Assay N2a 
cells were seeded and treated with 2.4 
mg/mL or 200 μM PA and cotreated 
with NAC at the indicated 
concentrations for 24 hours.  
Untreated cells were used as control 
group.  Cell viability was then 
measured via MTT assay.  Data are 
presented as mean ±  SD; n=8.  * 
indicated significant difference from 
the BSA/0 μM NAC treatment group, 
p<0.05. 
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mM of PB for 24 hours.  Following this incubation an MTT assay was performed to determine 
cell viability in each treatment group.  Data were normalized to the control group. 
 None of the concentrations of PB used for treatment induced a significant change in cell 
viability in the BSA treatment groups when compared to the untreated control.  Cells treated with 
PA and 0 μM PB displayed a 21% reduction in cell viability when compared to cells treated with 
BSA.  Cotreatment with concentrations of PB from 25μM to 1 mM did not result in a statistically 
significant reversal of this decrease in cell viability (Fig. 3).
 
 
Cell Imaging 
 To directly visualize the effects of PA treatment on N2a cell viability and morphology 
cells were plated and allowed to rest overnight.  Cells were then washed with PBS before serum-
free EMEM supplemented with 2.4 mg/mL BSA or 100, 200, or 400 μM PA was added.  After a 
Fig 3 Effects of PA/PB 
Cotreatment on N2a Cell 
Viability as Measured by MTT 
Assay N2a cells were seeded and 
treated with 2.4 mg/mL or 200 μM 
PA and cotreated with PB at the 
indicated concentrations for 24 
hours.  Untreated cells were used as 
control group.  Cell viability was 
then measured via MTT assay.  
Data are presented as mean ±  SD; 
n=6 
 
12 
 
24 hour incubation period the culture wells were washed to remove non-adherent cells before 
being imaged at 400X magnification. 
 Imaging of the BSA  treatment group showed a fairly consistent size and morphology 
among all cells in the field of view.  They were generally round and each extended several 
projections from the cell body into surrounding environment (Fig. 4A).  PA treatment was 
associated with a dose-dependent decrease in the number of adherent cells, as well as the number 
of projections extending from each cell.  PA treatment also appeared to induce an increased 
variability in cell size when compared to the BSA treatment group (Fig 4B-D).  
 
 
Insulin-Induced AKT1 Activation 
 To determine whether insulin exposure induced AKT1 phosphorylation in our cell line, 
N2a cells were plated and allowed to rest overnight.  Cells were then washed and incubated in 
serum-free media containing 2.4 mg/mL BSA for 24 hours.  Cells were subsequently challenged 
Fig 4 Effects of 
PA Treatment 
on Cell 
Confluence and 
Morphology 
Cells were 
incubated for 24 
hours in 2.4 
mg/mL BSA 
(A), 100 μM PA 
(B), 200 μM PA 
(C), or 400 μM 
PA (D) and then 
imaged at 400X 
magnification.  
Scale bar 
indicates 10 μm. 
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with 25 ng/mL insulin for 0, 5, or 10 minutes.  Protein was isolated from these cells and analyzed 
by Western blotting to determine the levels of the phosphorylated and total forms of AKT1.  The 
intensity of each protein band was then quantified and plotted as the relative level of phospho- to 
total AKT1. 
 Analysis of the Western blotting quantification data showed an increase in AKT1 
activation in both the 5 and 10 minute treatment groups (Fig. 5). 
    
Insulin-Induced GSK-3β Activation 
To determine whether insulin exposure induced GSK-3β phosphorylation in the N2a cell 
line, aliquots were taken from the protein samples collected in the previous insulin time course 
experiment and analyzed by Western blotting to determine the levels of the phosphorylated and 
total forms of GSK-3β.  The intensity of each protein band was then quantified and plotted as the 
relative level of phospho- to total GSK-3β. 
A 
B 
Fig 5 Effects of Insulin 
Treatment on AKT1 
Activation  
(A) Western blot to detect p-
AKT1 and total AKT1 
performed using protein 
extracted from N2a cells 
challenged with 25 ng/mL 
insulin for 0, 5, or 10 minutes.   
(B) Quantification of Western 
blot bands plotted as the level 
of p-AKT1 normalized to the 
amount of total AKT1.  Data 
are presented as mean ± SD; 
n=3.  * indicates significant 
difference from the 0 minute 
stimulation group, p<0.05. 
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 Analysis of the Western blotting quantification data for GSK-3β phosphorylation showed 
that cells treated with insulin exhibited increased GSK-3β activation in at both 5 and 10 minutes 
following treatment.  The increase in phosphorylation seen at 5 minutes did not reach statistical 
significance when compared to the control group, however (Fig. 6). 
   
Impact of PA Treatment on Insulin-Induced AKT1 Activation 
 To investigate the effects of PA treatment on the degree of AKT1 phosphorylation in our 
cell line, we seeded N2a cells and incubated them in serum free media supplemented with 2.4 
mg/mL BSA or 200 μM PA for 24 hours.  At the end of this treatment period the cells were 
stimulated with 25 ng/mL insulin for 0, 5, or 10 minutes.  Protein was then collected and 
analyzed by Western blotting to determine the levels of phospho- and total AKT1.  The intensity 
A 
B 
Fig 2 Effects of Insulin on GSK 
Activation (A) (B) n=3 
B 
Fig 6 Effects of 
Insulin Treatment on 
GSK-3β Activation  
(A) Western blot to detect 
p-GSK-3β and total GSK-
3β performed using protein 
extracted from N2a cells 
challenged with 25 ng/mL 
insulin for 0, 5, or 10 
minutes.    
(B) Quantification of 
Western blot bands plotted 
as the level of p-GSK-3β 
normalized to the amount 
of total GSK-3β.  Data are 
presented as mean ± SD; 
n=3.  * indicates significant 
difference from the 0 
minute stimulation group, 
p<0.05. 
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of each protein band was then quantified and plotted as the relative level of phospho- to total 
AKT1. 
Preliminary results from this experiment were consistent with our previous finding.  
BSA-treated cells that were challenged with insulin for 0 minutes showed a relatively low level 
of AKT1 activation.  Insulin challenge for 5 and 10 minutes in the BSA treatment group was 
associated with an increase in AKT1 phosphorylation.  The PA treatment group that was 
challenged with insulin for 0 minutes also displayed a low level of baseline AKT1 
phosphorylation.  Insulin challenge for 5 and 10 minutes in the PA treatment group appeared to 
be associated with an increase in AKT1 phosphorylation, though neither of these result 
represented statistically significant increase when compared to the PA-treated 0 minute challenge 
group (Fig. 7).  Insulin-induced AKT1 activation in PA treated cells appeared to be attenuated 
when compared to activation in BSA treated cells, but we were unable to replicate these 
provisional results with further experimentation due to technical complications. 
16 
 
 
  
 
Impact of PA Treatment on Insulin-Induced GSK-3β Activation 
To determine whether PA treatment had an impact on GSK-3β activation in the N2a cell 
line, aliquots were taken from the protein samples collected in the previous PA treatment 
experiment and analyzed by Western blotting to determine the levels of phospho- and total GSK-
3β.  The intensity of each protein band was then quantified and plotted as the relative level of 
phospho- to total GSK-3β. 
Preliminary results for this experiment suggested that BSA-treated cells that were 
challenged with insulin for 0 minutes showed a relatively low level of GSK-3β activation.  
Insulin challenge for 5 and 10 minutes in the BSA treatment group resulted in increased GSK-3β.  
The 0-minute insulin challenge group that had been pretreated with PA also displayed a low 
Fig 7 Effects of PA 
Treatment on 
Insulin-Induced 
AKT1 Activation  
(A) Western blot to 
detect p-AKT1 and 
total AKT1 performed 
using protein 
extracted from N2a 
cells treated with 2.4 
mg/mL BSA or 200 
μM PA for 24 hours 
and then challenged 
with 25 ng/mL insulin 
for 0, 5, or 10 
minutes.   
(B) Quantification of 
Western blot bands 
plotted as the level of 
p-AKT1 normalized 
to the amount of total 
AKT1.  Data are 
presented as mean ± 
SD; n=3.   
 
A 
B 
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level of baseline GSK-3β phosphorylation.  Insulin challenge for 5 minutes also appeared to 
increase GSK-3β phosphorylation (Fig. 8).  Insulin-induced activation of GSK-3β in PA-treated 
cells did not appear to differ substantially from the activation see in control cells.  We were 
unable to repeat these provisional results with further experimentation due to technical 
complications. 
 
 
 
 
 
 
 
 
 
Fig 8 Effects of PA 
Treatment on 
Insulin-Induced 
GSK-3β Activation  
(A) Western blot to 
detect p-GSK-3β and 
total GSK-3β 
performed using 
protein extracted 
from N2a cells treated 
with 2.4 mg/mL BSA 
or 200 μM PA for 24 
hours and then 
challenged with 25 
ng/mL insulin for 0, 
5, or 10 minutes as 
indicated.    
(B) Quantification of 
Western blot bands 
plotted as the level of 
p-GSK-3β normalized 
to the amount of total 
GSK-3β.  Data are 
presented as mean ± 
SD; n=3.   
 
A 
B 
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Discussion 
 
 This study was aimed at investigating the impact of PA treatment on cell viability and 
insulin signaling in neuronal cells.  We first sought to study the impact that exposure to elevated 
FFA levels had on cell viability.   Cells from the mouse neuroblastoma line N2a were initially 
treated with varying concentrations of PA for 24 hours.  At the end of this incubation period an 
MTT assay was used to determine the relative number of viable cells remaining.  Treatment with 
25 μM PA for 24 hours was associated with a slight increase in cell viability compared to the 0 
μM PA control group.  The relatively low level of PA in this treatment group may have caused 
this increase by providing an additional source of energy for the cells without negatively 
impacting cell health, thereby facilitating increased cell proliferation. Cells that were treated 50 
μM and 100 μM did not show a significant alteration in viability when compared to controls, but 
treatment with 200, 400, and 600 μM PA was associated with a dose-dependent reduction in 
viability.  These results correspond to findings in other cell types and suggest that elevated levels 
of FFAs can have a marked impact on the health of neuronal cells. 
Next, an attempt was made to determine whether treatment with the ROS scavenger NAC 
or the ER stress attenuator PB was able to reverse the decrease in cell viability caused by PA 
treatment.  Cells were treated with 2.4 mg/mL BSA or 200 μM PA as well as varying 
concentrations of NAC or PB for 24 hours before an MTT assay was used to determine the 
relative cell viability.  In both the NAC and PB cotreatment experiments, PA treated cells 
experienced a significant reduction in cell viability when compared both to untreated controls 
and the BSA treatment groups.  None of the concentrations of NAC or PB used for cotreatment 
was able to generate significant alterations in cell viability in either the BSA or PA treatment 
groups.  These results suggest that the reduction in cell viability we observed may not be caused 
19 
 
by ER stress or ROS.  Despite the fact that the results did not reach statistical significance, 
treatment with 200 μM, 500 μM, and 1 mM PB appeared to cause a small increase in cell 
viability in both the BSA- and PA-treated cells.  Studies using a larger number of samples may 
help clarify the impact of this chemical on cell survival.  Treatment with other ER stress 
attenuators, such as phenylproprionate, or ROS scavengers, such as coenzyme Q10, may also be 
justified to clarify the role of these processes following FFA exposure.
29-30 
In addition we performed an imaging study where cells were treated with different 
concentrations of PA and visualized with a microscope to support the findings of our initial MTT 
assay.  When compared to the BSA treated control group the 100, 200, and 400 μM PA treatment 
groups displayed a dose-dependent decrease in cell confluence.  Exposure to elevated levels of 
PA was also associated with alterations in cell size and morphology when compared to controls.  
These data taken with the results of our MTT assay suggest that PA, especially at high levels, has 
a profound impact on cell health and consequently on cell survival.  It is possible that these 
effects may be mediated by PA acting on mitochondria to impair their function, thereby reducing 
the amount of ATP available for proper cell growth and proliferation.  Exposure to PA may also 
cause the mitochondria to generate pro-apoptotic signals.
31
   
 Next we investigated the time course of insulin signaling in N2a cells and the effects of 
PA on this signaling pathway.  We found that insulin challenge induced significant AKT1 
activation at 5 and 10 minutes and significant GSK-3β activation at 10 minutes when compared 
to controls.  Cells were then treated with either 2.4 mg/mL BSA or 200 μM PA for 24 hours 
before challenging with insulin for 0, 5 or 10 minutes.  Preliminary results suggest that 5 and 10 
minute insulin challenge in the BSA-treated group may generate an increase in AKT1 activation.  
Insulin challenge in the PA-treated group for both 5 and 10 minutes, however, was not associated 
20 
 
with any significant alteration in AKT1 phosphorylation.  Cells in the BSA treatment groups also 
displayed a statistically significant increase in GSK-3β phosphorylation with 5 and 10 minute 
insulin challenge when compared to the 0 minute group.  Insulin challenge for 5 minutes in the 
PA treatment group appeared to generate a significant increase in GSK-3β activation when 
compared to the PA-treated 0 minute challenge group.  No significant alteration in GSK-3β 
activation was noted between the PA-treated 0 and 10 minute insulin challenge groups.   
These data suggest that exposure to PA may result in attenuated insulin signaling in 
neuronal tissue, but we were unable to replicate these results with further experimentation due to 
technical complications.  Though initial experiments probing for phospho- and total AKT1 
yielded acceptable results, subsequent Western blots performed according to the same procedure 
were marked by a band of unknown identity.  This band, though it did not overlie the bands of 
interest, was of such high intensity that it obscured the signals for phospho- and total AKT1 and 
prevented accurate analysis of these bands.  Experimentation regarding the effects of PA on 
GSK-3β activation was similarly hindered by technical issues.  Initial experiments utilizing a 
different antibody set were unable to generate a reliable signal for p-GSK.  Though this was 
eventually resolved through the use of the reagents listed above, funding and time constraints 
prevented the continued experimentation needed to validate our results.  It is also possible that 
the cell death caused by PA treatment in these experiments may have confounded our results.  
Though the PA treatment groups were initially seeded with more cells than the BSA treatment 
groups there were notably more cells in the wells that had received BSA at the time protein was 
collected.  The degree of cell death appeared to be higher than that observed during the MTT 
assays for cell viability and may be a result of the media used for each experiment.  Experiments 
in other cell lines have suggested that FBS exhibits a protective effect against the effects of PA 
21 
 
on cell viability.
24
  Since the media used for the MTT assays contained FBS and the media used 
for the insulin treatment experiments was serum-free, this may account for the increased cell 
death noted in the insulin signaling experiments.  Based on these findings future studies could be 
warranted to clarify the effects of PA treatment on AKT1 and GSK-3β activation, as well as to 
determine whether PA treatment is associated with the activation of JNK or p38 as is seen in 
other tissues.  Should these experiments be performed, however, steps should be taken to further 
compensate for PA-induced cell death and ensure that approximately equal amounts of protein 
are collected from all treatment groups.  Studies looking for the addition of inhibitory serine or 
threonine phosphate groups to upstream elements of the insulin signaling cascade in response to 
PA treatment may also be reasonable. 
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